ALSO NOTED: FazaClo OK'd; Swiss order Novartis to pull Zelmac/Zelnorm;and much more...

> Shares of Avanir Pharmaceuticals were surging this morning after the FDA approved a new formulation of its antipsychotic FazaClo. Release

> Swiss authorities have ordered Novartis to pull Zelmac/Zelnorm from the market after determining that the risks presented by the irritable bowel syndrome drug were greater than the benefits. Report

> Amicus Therapeutics priced its IPO at $15 a share, right in the middle of its forecasted range. Amicus expects to raise about $68 million. Report

> Australia's Chemeq, an agricultural bio company once worth more than $800 million, has been put in the hands of the administrators Report

> Jazz Pharmaceuticals has cut its price range on its IPO to $20 to $21 a share from an anticipated $24 to $26 a share. Report

> Cypress Bioscience has priced a public offering of 4.7 million shares at $15.50 a share. Release

> A federal judge has ordered a third trial in a Vioxx case after determining that one of Merck's witnesses misrepresented his qualifications. Report

> The Cleveland Clinic cardiologist whose research created a furor over Avandia now says that an FDA spokesman has targeted him for a smear campaign. Report

And Finally… Health officials are trying to determine what went wrong when a man diagnosed with a highly contagious form of drug resistant TB ended up on two international flights. The case points to some troubling problems with containing other potential pandemics. Article

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.